Moody's upgrade and rationale
Moody's Ratings raised HealthEquity, Inc.'s corporate family rating to Ba2 from Ba3 and upgraded its probability of default rating to Ba2-PD from Ba3-PD. The ratings agency also improved the grade on the company's $600 million senior unsecured notes to Ba3 from B1. Moody's retained the speculative grade liquidity rating at SGL-1 and revised the outlook to stable from positive.
Drivers behind the upgrade
Moody's attributed the upgrades to HealthEquity's continued positive operating results and the smooth integration of its BenefitWallet acquisition. According to the agency, the acquisition expanded scale and enhanced free cash flow generation, which permitted faster debt paydown than initially projected and produced lower financial leverage when measured by debt to EBITDA.
Moody's quantified leverage metrics for the twelve months ended April 30, 2026: debt to EBITDA, excluding capitalized software costs, was 2.1 times, representing about a full turn of improvement versus the prior fiscal year end. Interest coverage, calculated as EBITDA less capital expenditures divided by interest expense, stood at 9.0 times. The company reported EBITDA margins in the low to mid-30s percent range.
Moody's highlighted HealthEquity's market position as the largest non-bank custodian of Health Savings Accounts in the United States. For the same twelve-month period ending April 30, 2026, the company produced more than $400 million of free cash flow, an amount Moody's noted is roughly 40% of total debt.
Scale, capital policy and rating constraints
The rating agency noted constraints on the rating related to the company's revenue scale. Revenue for the twelve months ended April 30, 2026 exceeded $1.3 billion, which Moody's indicated remains below the revenue profiles of many Ba2-rated business services peers. Moody's also pointed to downside risks: a softer labor market or a lower interest rate environment could slow organic growth and place pressure on profitability.
Moody's flagged the potential for a more shareholder-friendly capital return stance following a May increase of HealthEquity's share buyback program by $1 billion. That upsized buyback contributes to rating constraint, although Moody's noted that only $547 million of the total $1.6 billion authorization has been repurchased to date.
Liquidity and debt structure
HealthEquity's liquidity position was described as very good by Moody's. The company held about $265 million of cash as of April 30, 2026. Moody's expects free cash flow of roughly $400-450 million per year in fiscal years 2027 and 2028. The agency anticipates about $600 million will remain available under the company's $1 billion revolver over the next 12 to 15 months.
Moody's assigned a Ba3 rating to the $600 million 4.5% senior unsecured notes due 2029, one notch below the Ba2 corporate family rating to reflect subordination to secured obligations.
Summary points
- Moody's upgraded HealthEquity's corporate and probability of default ratings and improved the rating on $600 million of senior unsecured notes.
- Improved free cash flow following the BenefitWallet integration enabled faster debt reduction and materially lower leverage metrics for the most recent twelve months.
- Liquidity is assessed as strong with cash on hand and expected free cash flow supporting near-term revolver availability.
Key sectors impacted
- Healthcare financial services - custody and HSA administration
- Corporate credit markets - debt investors and high-yield debt pricing
Risks and uncertainties
- A weaker labor market could damp organic growth and weigh on profitability in the near term.
- A lower interest rate environment could reduce net interest-related revenue or margin, moderating growth.
- An expanded or accelerated share buyback program could limit balance sheet flexibility; only $547 million of the $1.6 billion authorization has been repurchased so far.
Moody's view reflects improved operating cash generation and reduced leverage, while factoring in revenue scale limitations and potential macro and capital allocation risks.